So he left and started what became Nektar Therapeutics with Robert Platz of the Stanford Research Institute.
"We don't want to go there, " says John S. Patton, Nektar's founder and chief scientific officer.
Nektar cofounder John Patton, a marine biologist by training, got into inhaled drug delivery almost by accident.
Shares in Pfizer's partner in Exubera, Nektar Therapeutics, fell 15% in premarket trading.
That is the approach being taken by Ziopharm Oncology and by Nektar Therapeutics.
Many could be generic drugs that will benefit from one of Nektar's drug-delivery technologies and then be marketed as new medicines.
Gill says the drug-delivery business is strong enough to make Nektar profitable by 2006 even without the bump from Exubera, however.
"Nobody thought you could do this and make it reliable, " says John Patton, chief scientific officer of Nektar and a cofounder.
Nektar is the company that focused for years on developing an inhaled insulin product with Pfizer that ended up being a total flop.
One of Nektar's earliest hires was Adrian Smith, a mechanical engineer who had designed ink-jet printers for Hewlett-Packard and medical devices at venerable design firm IDEO.
So he left and started what became Nektar Therapeutics (nasdaq: NKTR - news - people ) with Robert Platz of the Stanford Research Institute.
But the hard work of inventing a powdered insulin and a delivery device that produces relief in a whiff was done by a determined group of scientists and engineers at Nektar Therapeutics.
One of Nektar's earliest hires was Adrian Smith, a mechanical engineer who had designed ink-jet printers for Hewlett-Packard (nyse: HPQ - news - people ) and medical devices at venerable design firm IDEO.
When mechanical engineer James Parks joined Nektar in 1994, employees at the company were hand-filling blister packs with an early version of insulin powder at a rate of 100 per person per day, too slow for mass production.
The idea of inhaled medicine goes back to German experiments with insulin in 1925 and continues with Inhale Therapeutic Systems, which went public in 1994 (recently renamed Nektar Therapeutics (nasdaq: NKTR - news - people )).
Exactly how that breadth is suggested by the new name is unclear, however: The former Inhale (nasdaq: INHL - news - people ) will now be known as Nektar and trade on Nasdaq under the ticker symbol NKTR.
Since Exubera, being co-developed with Pfizer and Aventis (nyse: AVE - news - people ), is expected to be a blockbuster, Nektar's share of sales would be huge if the U.S. Food and Drug Administration approves the drug.
But the hard work of inventing a powdered insulin and a delivery device that produces relief in a whiff was done by a determined group of scientists and engineers at Nektar Therapeutics (nasdaq: NKTR - news - people ).
Nektar therapeutic's engineering feat--the first insulin inhaler for adult diabetics--required inventing a way to turn liquid insulin into a powder of uniform particles just 2 microns wide (one one-thousandth the width of a pinhead), each containing hundreds of millions of stable insulin molecules.
After experimenting with more than a dozen different formulations, drying them with custom-made machinery and heating them in ovens to test shelf life, Nektar hit upon a successful recipe that mixes insulin with glycine (an amino acid), citrate (the salt of an organic acid found in humans) and mannitol (a sugar used in intravenous products).
To achieve these feats, Nektar's scientists performed hundreds of hours of computer simulations, tested more than a dozen different formulations of dried insulin and traveled around the world drawing inspiration from ancient Chinese seeds, plants in the Mexican desert and production techniques used in making instant coffee, powdered milk, aviation aerodynamics, truck fuel injectors and industrial vacuum pumps.
应用推荐